GlassScriptPhysician profile
Daniel Michael Feckoury
NPI 1659516367
$1,114.27
in general payments reported to CMS, 2019-2025
20 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $84.93 · 2021: $132 · 2022: $50.91 · 2023: $312 · 2024: $272 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $223.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $131.43 | 2019-2025 | |
| Viiv Healthcare Company | $115.74 | 2022-2025 | Apretude |
| Lilly USA, LLC | $80.27 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $69.53 | 2019-2024 | Veozah |
| Abbvie INC. | $61.51 | 2020-2025 | |
| Amgen INC. | $55.85 | 2020-2021 | |
| Exact Sciences Corporation | $50.27 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $39.30 | 2021-2024 | Gardasil 9, Gardasil |
| Abbott Laboratories | $39.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.96 | 2024 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.40 | 2019-2020 | |
| Axsome Therapeutics, INC. | $32.31 | 2025 | Symbravo |
| Nevro Corp. | $27.03 | 2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $22.43 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.25 | 2023 | Shingrix |
| Dynavax Technologies Corporation | $22.25 | 2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $18.71 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.51 | 2019 | |
| Amarin Pharma, INC. | $17.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Feckoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.